Table 3.
Baseline characteristics of HCV/HIV co-infected patients (HCV treated versus untreated)
| Characteristics | Group A: HCV/HIV co-infected patients, treated (n = 36) | Group B: HCV/HIV co-infected patients, untreated (n = 52) | p-values |
|---|---|---|---|
|
Age, mean (min./max.) |
47 (26/64) |
45 (27/61) |
0.040 |
|
Sex, male/female (%) |
26/10 (72/28) |
40/12 (77/23) |
0.617 |
|
Genotype, n (%) |
|
|
|
| 1 |
15 (42) |
22 (42) |
0.952 |
| 2 |
2 (6) |
1 (2) |
0.356 |
| 3 |
14 (39) |
11 (21) |
0.070 |
| 4 |
1 (2) |
1 (2) |
0.791 |
| Unknown |
4 (11) |
17 (33) |
0.020 |
|
Transmission of HCV, n (%) |
|
|
|
| IVDU |
21 (58) |
37 (71) |
0.212 |
| Transfusion |
4 (11) |
3 (6) |
0.363 |
| Needlestick injury |
0 (0) |
0 (0) |
n.a. |
| Tatoo |
0 (0) |
0 (0) |
n.a. |
| Sex |
1 (3) |
3 (6) |
0.508 |
| Unknown |
10 (28) |
9 (17) |
0.241 |
|
CDC Classification, n (%) |
|
|
|
| A1 – A3 |
13 (36) |
10 (19) |
0.005 |
| B1 – B3 |
9 (25) |
7 (13) |
0.168 |
| C1 – C3 |
9 (25) |
22(42) |
0.059 |
| Unknown |
5 (13) |
14 (26) |
0.144 |
|
Liver biopsy, n (%) |
7/36 (19) |
5/52 (9) |
0.186 |
| Fibrosis F3 – F4, n (%) |
5/7 (71) |
1/5 (20) |
0.029 |
|
HCV RNA in IU/ml, mean (min./max.) |
4800 000 (800/9 × 107) |
4 713 000 (3/6 × 107) |
0.965 |
|
CD4 Count absolute, mean |
553,1 |
396,73 |
0.001 |
| CD4 Count > 200/μl, n (%) |
25 (69) |
21 (40) |
0.007 |
| CD4 Count < 200/μl, n |
2 (3,5) |
16 (30) |
0.004 |
| CD4 Count unknown, n (%) |
7 (19) |
15 (28) |
0.317 |
|
CD4 Count relative, mean |
27,9 |
22,2 |
0.001 |
|
CD4 Nadir in cells/μl, mean |
208 |
194 |
0.689 |
|
CD4/CD8 Ratio, mean |
0,67 |
0,49 |
0.001 |
|
HIV RNA in copy/ml, mean (minimum/maximum) |
9 850 (3/16 × 104) |
71 180 (3/12 × 105) |
0.015 |
|
HIV Treatment, n (%) |
29 (36) |
0 (0) |
n.a. |
| NRTI, n (%) |
20/29 (68) |
n.a. |
n.a. |
| NNRTI, n (%) |
18/29 (62) |
n.a. |
n.a. |
| PI, n (%) |
12/29 (41) |
n.a. |
n.a. |
| Intregrase Inh., n (%) |
2/29 (6) |
n.a. |
n.a. |
| Entry Inh., n (%) | 0 (0) | n.a. | n.a. |